

HBP SURGERY WEEK 2022

MARCH 3 THU - 5 SAT, 2022 CONRAD HOTEL, SEOUL, KOREA www.khbps.org





The Use Of 18F-FDG Positron Emission Tomography To Predict Tumour Recurrence In Hepatocellular Carcinoma Patients After Hepatectomy

Jun ZHENG*1, Tiffany CL WONG2, Jeff WC DAI2, Albert CY CHAN2, Tan-To CHEUNG2, Chung-Mau LO2

Background: A reliable biomarker to predict hepatocellular carcinoma (HCC) recurrence after hepatectomy is lacking. We hypothesized that pre-operative 18F-fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography (PET) predicted HCC recurrence after hepatectomy.

Methods: This was a retrospective study of prospective collected data between 2004–2019. The cut-off for 18F-FDG uptake on PET for HCC recurrence was determined by Youdens' index. Patients were stratified into PET+ve and PET-ve group. Baseline, pathological characteristics, disease-free and overall survival rates were compared.

Results: 267 patients underwent hepatectomy with preoperative PET scan. The cut-off for 18F-FDG PET positivity was 1.526 (AUC=0.674, 95% CI 0.608–0.741, P \langle 0.001 \rangle 1. 155 patients were PET-ve and 112 patients were PET+ve. The PET+ve group had larger tumors (8.25 vs. 3.5cm, P \langle 0.001 \rangle 1, more microvascular invasion (67 vs. 36.1%, P \langle 0.001 \rangle 1, more poorly differentiated tumours (24.8 vs. 16.7%, P=0.03) and higher AFP≥100ng/mI (49.1 vs. 23.2% P \langle 0.001 \rangle 1. The time to recurrence was shorter in PET+ve patients (8.4 vs. 32.7 months, P \langle 0.001 \rangle 1) and there was more extrahepatic recurrence (8.9 vs. 2.6%, P \langle 0.001 \rangle 1. The PET-ve group had better overall and disease-free survival rates at 1-, 3- and 5-year respectively (96.1%, 84.9%, 79.8% vs. 78.2%, 54.9%, 43.1%, P \langle 0.001 \rangle 1, 74.6%, 55.2%, 45.8% vs. 43%, 37.1%, 33.1%, P \langle 0.001 \rangle 1

Conclusions: PET+ve was associated with higher AFP and unfavourable tumour biology, with a higher risk of recurrence and inferior survival. 18F-FDG PET should be explored prospectively as a biomarker in HCC patients.

Corresponding Author: Jun ZHENG (junzheng198723@gmail.com)

¹Surgery, Queen Mary Hospital, HONG KONG

²Surgery, University Of Hong Kong, HONG KONG